BG T&A Co. (KOSDAQ:046310)
South Korea · Delayed Price · Currency is KRW 2,320.00
-10.00 (-0.43%)
At close: Sep 18, 2026
BG T&A Co. Revenue
BG T&A Co. had revenue of 39.54B KRW in the quarter ending June 30, 2026, with 4.09% growth. This brings the company's revenue in the last twelve months to 144.65B, down -9.00% year-over-year. In the year 2025, BG T&A Co. had annual revenue of 148.92B, down -2.34%.
Revenue (ttm)
144.65B
Revenue Growth
-9.00%
P/S Ratio
0.26
Revenue / Employee
2.41B
Employees
60
Market Cap
37.31B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 148.92B | -3.57B | -2.34% |
| Dec 31, 2024 | 152.49B | -18.24B | -10.68% |
| Dec 31, 2023 | 170.73B | 23.13B | 15.67% |
| Dec 31, 2022 | 147.60B | -8.86B | -5.66% |
| Dec 31, 2021 | 156.46B | 23.69B | 17.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nara Mold & Die | 184.03B |
| Okong | 169.03B |
| Photon | 139.52B |
| YounglimwonSoftLab Co.Ltd | 85.58B |
| Seoulin Bioscience | 83.17B |
| Korean Drug | 65.39B |
| CNTUS Co.,Ltd | 62.50B |
| Biotoxtech | 52.48B |